Company intelligence / Profile preview

PPF Group

Prague, Czech Republic

Ownership: Private
Employees: ~55000
Development stage: Other

Overview

PPF invests in innovative oncology/immune therapies through majority ownership (e.g., SOTIO) and minority stakes (e.g., Autolus). SOTIO’s DCVAC and interleukin-15 superagonist programs have progressed into clinical trials, including recent Phase I/Ib. Autolus’s AUTO1 CAR-T program entered pivotal Phase II in relapsed or refractory adult ALL

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateCell therapyGene therapyDendritic cell therapyInterleukin-15 superagonist therapyViral vector
Industry: Investors

Partnerships

NBE-Therapeutics (ADC technology)eureKING (CDMO/biomanufacturing, post SCTbio transaction)Cellestia Biotech (switzerland)Lead Discovery Center

Beyond the preview

Go deeper on PPF Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPF Group.

Explore the full profile